11/7/2019 4:05:05 PM
Arena Pharma Q3 Loss/share $1.46 Vs. Loss $0.70 Year Ago
11/6/2019 8:35:01 AM
Arena Presents New Data Highlighting Human Mass Balance And Metabolism Profile Of Etrasimod
10/28/2019 8:31:59 AM
Arena Pharmaceuticals Says First Subject Dosed In Phase 2 ADVISE Trial Evaluating Etrasimod
10/18/2019 3:09:26 AM
Arena Pharma To Present New Open-label Extension Data From Phase 2 OASIS Trial For Etrasimod At UEG Week
9/26/2019 8:38:40 AM
Arena Pharmaceuticals Presents New Data From Phase 2 OASIS Trial For Etrasimod
9/9/2019 8:32:36 AM
Arena Presents New Patient-Reported Outcomes Data For Olorinab
8/7/2019 4:04:54 PM
Arena Q2 Loss Per Share Of $1.24 Vs. $0.65 Last Year
7/25/2019 8:32:24 AM
Arena Says First Subject Dosed In Phase 2 CAPTIVATE Trial Evaluating Olorinab
6/17/2019 8:31:54 AM
Arena Announces First Subject Dosed In ELEVATE UC 52 Global Phase 3 Trial On Etrasimod In Ulcerative Colitis
5/21/2019 7:31:29 AM
Corvidia Therapeutics Appoints Preston Klassen To Board
5/17/2019 8:32:47 AM
Arena Pharma Initiates Sites For ELEVATE UC Phase 3 Global Program To Evaluate Etrasimod 2 Mg
5/8/2019 4:06:14 PM
Arena Pharma Q1 EPS $12.10 Vs. Loss $0.80 Year Ago